Several preformulation characteristics of a series of novel HIV protease inhibitors were examined as a prelude to expedient oral dosage form development.Initial studies indicated that these compounds were orally bioavailable in rats (≤39%), but chem. unstable at low pH.AG1284 was selected as the lead compound from the series for further preclin. development based on its relatively high oral bioavailability and stability.The pH-rate profiles of AG1284 indicated a first-order degradative loss of a dimethylbenzyl group under acidic conditions.Concentrated solutions of an amorphous form prepared in various pharmaceutical solvents exhibited precipitation on standing.The precipitate was identified as crystalline AG1284 by X-ray powder diffraction, DSC, and polarized light/hot stage microscopy, and its solubility in water proved to be much lower than that of the amorphous form.Oral administration in dogs of a solid blend of AG1284 with polyethylene glycol 3350 (PEG 3350) in enteric-coated hard gelatin capsules did not yield any detectable AG1284 levels in plasma.When dosed in a propylene glycol/water (60/40) solution at 50 mg/kg to rats, oral bioavailability and Cmax were 39% and 2.8 μg/mL, resp.When delivered in a lyophilizable emulsion to rats at 100 mg/kg, oral bioavailability and Cmax were 31% and 3.0 μg/mL, resp.The lyophilized product could be reconstituted with WFI to regenerate an emulsion.